Phaseline

Targets › ABCC8

ABCC8 (ATP-binding cassette sub-family C member 8): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Oncology, Neurology; next expected readout Dec 2026.

Regulator subunit of pancreatic ATP-sensitive potassium channel (KATP), playing a major role in the regulation of insulin release. In pancreatic cells, it forms KATP channels with KCNJ11; KCNJ11 forms the channel pore while ABCC8 is required for activation and regulation. (UniProt, Q09428)

Open in Phaseline: the race on ABCC8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RezoluteRZ358
ABCC8 activator (potassium channel opener)
ABCC8Phase 3Congenital HyperinsulinismNov 2027
Memorial Sloan Kettering Cancer CenterGlipizide
Sulfonylurea receptor 1, Kir6.2 blocker
Ion channels, ABCC8Phase 2Pancreatic CancerDec 2026
Francis FarhadiGlyburide
Sulfonylurea receptor 1, Kir6.2 blocker
Ion channels, ABCC8Phase 1Acute Spinal Cord InjuryMay 2027

Conditions

Congenital Hyperinsulinism (1) Pancreatic Cancer (1) Acute Spinal Cord Injury (1)

Modalities

small molecule (3)

Companies

Rezolute (1) Memorial Sloan Kettering Cancer Center (1) Francis Farhadi (1)

Related targets

Ion channels (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.